MAP3K3

MAP3K3, also known as MEKK3, functions as a serine/threonine kinase that initiates intracellular signaling cascades through the mitogen-activated protein kinase (MAPK) pathway^[1]. Mechanistically, MAP3K3 phosphorylates and activates downstream MAPK kinases, including MEK5, which in turn regulates ERK5 signaling critical for cell proliferation and stress responses^[1][2]. In disease models, aberrant MAP3K3 activity has been linked to cardiovascular dysfunction, inflammatory responses, and tumorigenesis, highlighting its pathophysiological significance^[3][4]. Compared with related isoforms such as MAP3K1 and MAP3K2, MAP3K3 exhibits distinct substrate specificity and regulatory domains that determine selective activation of the ERK5 cascade over other MAPK pathways^[2][5]. Agonists and inhibitors targeting MAP3K3 demonstrate differential modulation of endothelial and cardiac cell functions, offering tools for experimental studies on stress-induced signaling and therapeutic potential^[3][6]. Inhibitor studies reveal that selective blockade of MAP3K3 can suppress proinflammatory signaling while preserving parallel MAPK-mediated survival pathways, emphasizing isoform-specific effects in both in vitro and in vivo systems^[6]. Collectively, these findings position MAP3K3 as a central node in MAPK signaling with unique isoform-dependent roles and a valuable target for mechanistic and translational research applications^{[1][2][3][5][6]}.